In a reproductive‑age woman with polycystic ovary syndrome presenting with enlarged ovaries and peripheral follicles, what are the typical ovarian symptoms and the recommended initial evaluation and first‑line management?

PCOS Ovarian Symptoms and Management

Women with PCOS presenting with enlarged ovaries and peripheral follicles typically experience irregular menstrual cycles and signs of hyperandrogenism, and should be managed first-line with multicomponent lifestyle intervention including diet, exercise, and behavioral strategies. 1

Typical Ovarian Symptoms

The ovarian manifestations in PCOS are often asymptomatic from a direct ovarian standpoint, but result in reproductive dysfunction: 2

• Oligo/anovulation causing menstrual irregularities (cycles >35 days or irregular cycles 32-36 days) 3
• Infertility due to ovulatory dysfunction 4
• Increased risk of endometrial hyperplasia and cancer from unopposed estrogen exposure in anovulatory cycles 3

Ultrasound Findings

The characteristic ovarian morphology includes: 5

• Enlarged ovary size (≥10 mL volume threshold)
• Multiple small follicles (≥25 follicles measuring 2-9 mm in the whole ovary using modern ultrasound)
• Peripheral distribution of follicles ("string of pearls" appearance)
• Increased ovarian stromal volume and echogenicity
• Higher stromal blood flow

Initial Evaluation

Diagnostic Criteria

Use the Rotterdam criteria requiring 2 of 3 features: 4, 2

1. Hyperandrogenism (clinical or biochemical)
2. Ovulatory dysfunction (oligo/anovulation)
3. Polycystic ovaries on ultrasound

Critical caveat: The 2023 International Guideline now allows anti-Müllerian hormone (AMH) levels as an alternative to ultrasound in adults only (not adolescents). 6

Essential Exclusion Testing

Before confirming PCOS, exclude: 4, 2

• Androgen-secreting tumors (if marked virilization or rapid symptom onset)
• Congenital adrenal hyperplasia (17-hydroxyprogesterone levels)
• Thyroid dysfunction (TSH)
• Hyperprolactinemia (prolactin)

Biochemical Assessment

• Free testosterone is more sensitive than total testosterone and should be measured via equilibrium dialysis when possible 3
• 17-hydroxyprogesterone and AMH are useful for diagnosis 3
• Measuring androgens other than testosterone has relatively low value 3

Metabolic and Cardiovascular Screening

PCOS is now recognized as a cardiovascular disease risk-enhancing factor. 7 Screen for:

• Type 2 diabetes risk (PCOS patients are 4× more likely to develop diabetes) 2
• Metabolic syndrome (2× more common than general population) 2
• Cardiovascular disease risk factors including lipid profile and blood pressure 4
• Obstructive sleep apnea 4

Psychological Assessment

Screen for: 6, 4

• Depression and anxiety (very high prevalence in PCOS)
• Quality of life impairment
• Weight stigma concerns

First-Line Management

Lifestyle Intervention (Primary Treatment)

Multicomponent lifestyle intervention is the first-line management in the intervention hierarchy for PCOS. 1 This includes:

• Diet modification (no specific diet is superior; focus on healthy eating patterns) 1
• Regular exercise (beneficial even without weight loss) 8
• Behavioral strategies for sustainable change 1
• Weight loss of as little as 5% of initial weight improves metabolic and reproductive abnormalities 8

Important: Address weight-related health risks while minimizing weight stigma. 9

Management Based on Primary Concern

For Menstrual Irregularities and Endometrial Protection

• Combined oral contraceptive pills (OCPs) are first-line therapy 8, 4, 2
• Focus on low-dose preparations 9
• OCPs suppress ovarian androgen production and increase sex hormone-binding globulin 3
• Cyclic progestin if OCPs contraindicated (though optimal duration/frequency for endometrial cancer prevention is unknown) 8

For Metabolic Features

• Metformin is first-line for metabolic/glycemic abnormalities 4, 2
• Improves glucose tolerance and menstrual irregularities 8
• Limited or no benefit for hirsutism, acne, or infertility 4
• Interventions improving insulin sensitivity may positively impact diabetes and cardiovascular disease risk factors 8

For Hyperandrogenism (Hirsutism/Acne)

• OCPs are first-line therapy 8, 4, 2
• Anti-androgens (spironolactone, cyproterone acetate, flutamide, finasteride) can be added for resistant cases 3
• Combination therapy (anti-androgen plus OCP) appears most effective 8
• Mechanical hair removal methods (laser, electrolysis) as adjuncts 8

For Infertility (If Pregnancy Desired)

Treatment algorithm: 8

1. Weight control and regular exercise (first step)
2. Clomiphene citrate (first-line medication; 80% ovulate, 50% of ovulators conceive) 8
3. Letrozole (also first-line per recent evidence) 2
4. Low-dose gonadotropins if clomiphene fails (lower risk of ovarian hyperstimulation than high-dose) 8

Metformin improves ovulation frequency but effects on early pregnancy are uncertain; appears safe but documentation is limited. 8

Laparoscopic ovarian drilling has undetermined benefit/role. 8

Common Pitfalls to Avoid

• Do not use polycystic ovarian morphology on ultrasound for diagnosis in adolescents (<17 years) as multicystic ovaries are common findings in this age group 3, 9
• Do not use AMH levels for diagnosis in adolescents (adults only) 6, 9
• Avoid thiazolidinediones due to unfavorable risk-benefit ratio 4
• Do not delay evaluation indefinitely in adolescents; consider diagnosis 2 years post-menarche if criteria met 2
• Recognize that insulin resistance occurs regardless of BMI and affects both lean and overweight women 1